Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 7/20 | 0.44 |
| ▸ | KIT | P10721 | 1/20 | 0.42 |
| ▸ | FLT3 | P36888 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.38 |
| ▸ | ABL1 | P00519 | 1/20 | 0.37 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.37 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.37 |
| ▸ | TBK1 | Q9UHD2 | 4/20 | 0.37 |
| ▸ | IKBKE | Q14164 | 3/20 | 0.37 |
| ▸ | HRH2 | P25021 | 1/20 | 0.36 |
| ▸ | HRH1 | P35367 | 1/20 | 0.36 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL444535 | 0.82 | HDAC6 (0.51) | HDAC6KITFLT3HDAC1HDAC2 | |
| SCHEMBL4254200 | 0.76 | HDAC6 (0.43) | HDAC6KITFLT3HDAC1HDAC2 | |
| SCHEMBL443202 | 0.67 | HDAC6 (0.47) | HDAC6HDAC1HDAC2HDAC8HDAC3 | |
| SCHEMBL442957 | 0.66 | KIT (0.39) | KITFLT3MKNK1 | |
| SCHEMBL16914806 | 0.62 | ALDH1A1 (0.61) | — | |
| SCHEMBL4255461 | 0.61 | NPC1 (0.42) | HDAC6HDAC1HDAC2HDAC8 | |
| SCHEMBL404269 | 0.61 | HDAC6 (0.45) | HDAC6KITFLT3HDAC2HDAC8 | |
| SCHEMBL14880133 | 0.59 | ALOX15 (0.68) | HDAC6HDAC1HDAC2HDAC8HDAC3 | |
| SCHEMBL1109561 | 0.58 | HDAC6 (0.62) | HDAC6HDAC1HDAC2HDAC8HDAC3 | |
| SCHEMBL1109521 | 0.58 | HDAC6 (0.62) | HDAC6KITFLT3HDAC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8779171-B2 | Hydroxamates as therapeutic agents | PHARMACYCLICS, INC. (US) | 2014-07-15 | — | — | US | disclosed |
| US-20130142758-A1 | NOVEL HYDROXAMATES AS THERAPEUTIC AGENTS | PHARMACYCLICS, INC. (US) | 2013-06-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130142758-A1 | NOVEL HYDROXAMATES AS THERAPEUTIC AGENTS | HDAC1, HDAC3, HDAC5 | HDAC6 8/4885KIT 4582/4885FLT3 3746/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.